This invention relates to the treatment of tachyarrhythmias of supraventricular origin. This
condition may safely be treated by nasal administration of a composition comprising …

An injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions
comprising an effective amount of methyl 3-[4-(2-hydroxy-3-isopropylamino) propoxy] …

US Patent No. 3,639,169 discloses one such direct compression vehicle for a therapeutically
active medicament which consists of an insoluble or soluble diluent such as lactose …

Disclosed is a method for enhancing absorption of a medicament that is suitable for
administering transmucosally to a subject by providing an environment of the administration …

4,792,450 12/1988 Kydonieus et al...... 424/449 Sustained release excipient including a
gelling agent, an inert 4,792,452 12/1988 Howard et al....... 424/475 pharmaceutical diluent …

1987-12-21 Assigned to RORER PHARMACEUTICAL CORPORATION, 500 VIRGINIA
DRIVE, FORT WASHINGTON, PA. 19034, A DE. CORP. reassignment RORER …

ABSTRACT OF THE DISCLOSURE This invention relates to tablets for medicinal agents in
which the active substance is released at a controlled rate up to about 8 hours. The material …

The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of
valproic acid, and processes for preparing the compositions. The non-hygroscopic …

The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of
valproic acid, and processes for preparing the compositions. The non-hygroscopic …

In accordance with the principal aspect of the present invention, it has been found that the
bioavailability of non-parenterally administered leuprolide is considera bly enhanced by …